Immune thrombocytopenia (ITP) is an immune disease characterized by an increased risk of hemorrhagic disease caused by a decrease in platelet count. At present, the first line, second-line treatment can not completely or maintain continuous remission of ITP. New treatments in recent research include stimulating platelet-producing drugs, Syk inhibitors, and molecular-targeted drugs, etc., which can play a role in key steps of the progression of the disease. Among them, new types of drugs that stimulate thrombopoiesis shows a better therapeutic prospects with a comparative mechanism and clinical research, Syk inhibitors have a unique role in the treatment of malignant diseases in blood system, and the transplantation of mesenchymal stem cells is a new treatment idea. These treatments show the potential to improve the quality of life in patients with ITP. In this review, the latest research progress of new therapeutic drugs for ITP is summarized briefly.